jueves, 27 de junio de 2024

FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma

No hay comentarios:

Publicar un comentario